🇺🇸 FDA
Pipeline program

EryDex Low dose DSP

IEDAT-02-2015

Phase 3 small_molecule completed

Quick answer

EryDex Low dose DSP for Nervous System Disease is a Phase 3 program (small_molecule) at Quince Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Quince Therapeutics
Indication
Nervous System Disease
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials